[go: up one dir, main page]

ES2422657A1 - Composición farmacéutica sólida de cilostazol - Google Patents

Composición farmacéutica sólida de cilostazol

Info

Publication number
ES2422657A1
ES2422657A1 ES201230213A ES201230213A ES2422657A1 ES 2422657 A1 ES2422657 A1 ES 2422657A1 ES 201230213 A ES201230213 A ES 201230213A ES 201230213 A ES201230213 A ES 201230213A ES 2422657 A1 ES2422657 A1 ES 2422657A1
Authority
ES
Spain
Prior art keywords
cilostazol
relates
composition
solid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201230213A
Other languages
English (en)
Other versions
ES2422657B1 (es
Inventor
Tierno Jesus Grandio
Aijon Antonio Fernandez
Esteso Carlos Govantes
Sanchez Maria De Los Angeles Bueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Normon S A Lab
Original Assignee
Normon S A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Normon S A Lab filed Critical Normon S A Lab
Priority to ES201230213A priority Critical patent/ES2422657B1/es
Priority to PCT/ES2013/070072 priority patent/WO2013117793A1/es
Publication of ES2422657A1 publication Critical patent/ES2422657A1/es
Application granted granted Critical
Publication of ES2422657B1 publication Critical patent/ES2422657B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica sólida de cilostazol. - La presente invención se refiere a una composición farmacéutica sólida de cilostazol que comprende cilostazol como principio activo, un agente aglutinante que contiene una mezcla de un alcohol de azúcar y talco, y, opcionalmente, un agente disgregante. Dicha combinación de excipientes confiere una solubilidad apropiada al principio activo. También se refiere al uso de dicha composición para la preparación de formas farmacéuticas de cilostazol para su administración por vía oral. La invención se refiere también a comprimidos preparados con la composición de la invención, que presentan unas propiedades apropiadas en cuanto a la solubilidad y a la biodisponibilidad del cilostazol. También se refiere a procedimientos para preparar la composición y comprimidos de cilostazol, así como a su uso como medicamentos.
ES201230213A 2012-02-10 2012-02-10 Composición farmacéutica sólida de cilostazol Active ES2422657B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201230213A ES2422657B1 (es) 2012-02-10 2012-02-10 Composición farmacéutica sólida de cilostazol
PCT/ES2013/070072 WO2013117793A1 (es) 2012-02-10 2013-02-08 Composición farmacéutica sólida de cilostazol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230213A ES2422657B1 (es) 2012-02-10 2012-02-10 Composición farmacéutica sólida de cilostazol

Publications (2)

Publication Number Publication Date
ES2422657A1 true ES2422657A1 (es) 2013-09-12
ES2422657B1 ES2422657B1 (es) 2014-06-11

Family

ID=48946935

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230213A Active ES2422657B1 (es) 2012-02-10 2012-02-10 Composición farmacéutica sólida de cilostazol

Country Status (2)

Country Link
ES (1) ES2422657B1 (es)
WO (1) WO2013117793A1 (es)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058066A1 (en) * 2000-09-22 2002-05-16 Otsuka Pharmaceutical Co., Ltd. Cilostazol dry coated tablet
US7144585B1 (en) * 1999-03-25 2006-12-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
WO2009107864A2 (en) * 2008-02-29 2009-09-03 Otsuka Pharmaceutical Co., Ltd. An orally disintegrating tablet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144585B1 (en) * 1999-03-25 2006-12-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
US20020058066A1 (en) * 2000-09-22 2002-05-16 Otsuka Pharmaceutical Co., Ltd. Cilostazol dry coated tablet
WO2009107864A2 (en) * 2008-02-29 2009-09-03 Otsuka Pharmaceutical Co., Ltd. An orally disintegrating tablet

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JINNO, JUN-ICHI, et al; In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol; Journal of Controlled Release, volumen 130, número 1, páginas 29-37; 2008; ISSN 1873-4995. *

Also Published As

Publication number Publication date
WO2013117793A1 (es) 2013-08-15
ES2422657B1 (es) 2014-06-11

Similar Documents

Publication Publication Date Title
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX348823B (es) Formulaciones estables de linaclotida.
PH12015501096A1 (en) Composition for immediate and extended release
HK1221418A1 (zh) 释放修饰药物的水凝胶-连接的前药
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
TN2015000135A1 (en) Modified release formulations for oprozomib
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
MX370184B (es) Composición farmacéutica que comprende fingolimod.
ES2422657A1 (es) Composición farmacéutica sólida de cilostazol
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
IN2013MU01226A (es)
IN2013MU03656A (es)
WO2011107922A3 (en) Extended release composition of milnacipran
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
MX2013004248A (es) Composiciones farmaceuticas topicas que comprenden etodolaco.
GR1007907B (el) Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης
IN2013MU01944A (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2422657

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140611